Ignite Creation Date:
2025-12-24 @ 1:41 PM
Ignite Modification Date:
2025-12-24 @ 1:41 PM
Study NCT ID:
NCT01627795
Status:
SUSPENDED
Last Update Posted:
2018-04-18
First Post:
2012-06-20
Is Possible Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Safety and Efficacy of Oshadi D and Oshadi R for Malignant Mesothelioma Treatment
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D008654', 'term': 'Mesothelioma'}, {'id': 'D000086002', 'term': 'Mesothelioma, Malignant'}, {'id': 'D009369', 'term': 'Neoplasms'}], 'ancestors': [{'id': 'D000236', 'term': 'Adenoma'}, {'id': 'D009375', 'term': 'Neoplasms, Glandular and Epithelial'}, {'id': 'D009370', 'term': 'Neoplasms by Histologic Type'}, {'id': 'D018301', 'term': 'Neoplasms, Mesothelial'}, {'id': 'D008175', 'term': 'Lung Neoplasms'}, {'id': 'D012142', 'term': 'Respiratory Tract Neoplasms'}, {'id': 'D013899', 'term': 'Thoracic Neoplasms'}, {'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D010997', 'term': 'Pleural Neoplasms'}, {'id': 'D008171', 'term': 'Lung Diseases'}, {'id': 'D012140', 'term': 'Respiratory Tract Diseases'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE1', 'PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NA', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'SINGLE_GROUP'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 17}}, 'statusModule': {'overallStatus': 'SUSPENDED', 'startDateStruct': {'date': '2016-12'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2018-04', 'completionDateStruct': {'date': '2018-12', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2018-04-16', 'studyFirstSubmitDate': '2012-06-20', 'studyFirstSubmitQcDate': '2012-06-25', 'lastUpdatePostDateStruct': {'date': '2018-04-18', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2012-06-26', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2018-08', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Adverse events and serious adverse events occurence', 'timeFrame': 'One month following treatment initiation', 'description': 'Adverse events and serious adverse events report'}], 'secondaryOutcomes': [{'measure': 'overall survival time', 'timeFrame': '12 months', 'description': 'Overall survival time from treatment initiation'}]}, 'oversightModule': {'oversightHasDmc': False}, 'conditionsModule': {'keywords': ['Malignant Mesothelioma', 'Cancer', 'Anti cancer agents'], 'conditions': ['Mesothelioma']}, 'descriptionModule': {'briefSummary': 'Malignant mesothelioma is a rare neoplasm that arises most commonly from the mesothelial surfaces of the pleural cavity, occasionally from the peritoneal surface, and rarely from the tunica vaginalis or pericardium. It has an extremely poor prognosis with a median survival of 4 to 13 months for untreated patients 1 and 6 to 18 months for treated patients, regardless of the therapeutic approach.\n\nThe anticancer activity of Oshadi D and Oshadi R treatment was tested in preclinical studies and in phase I clinical study. Four metastatic mesothelioma patients are treated for 5 to 12 months. The Oshadi D and Oshadi R combination treatment was generally well-tolerated with no dose-limiting toxicities observed.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '21 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Histologically or cytologically proven diagnosis of malignant mesothelioma\n* Man or woman 21 years and above\n* Adequate performance status (ECOG 0, 1, or 2)\n* Patient must have adequate organ function as the following:\n\n * Absolute neutrophils counts (ANS) \\> 2500/μL.\n * Platelets \\> 150,000/μL.\n * Hemoglobin \\> 10 g/dL.\n * Total Bilirubin \\< 1.5 Upper Normal Limit (UNL).\n * Alanine aminotransferase (ALT), AST (aspartate aminotransferase)and alkaline phosphatase must be \\< 1.5 times of the upper limit of normal.\n * LDH (lactate dehydrogenase) \\< 500 int. unit/L\n * Estimated GFR (glomerular filtration rate) \\> 45 ml/min.\n* Written informed consent\n* Females of childbearing potential and males must be willing to use an effective method of contraception (hormonal or barrier method of birth control; abstinence) from the time consent is signed until 6 weeks after treatment discontinuation.\n* Females of childbearing potential must have a negative pregnancy test within 7 days prior to being registered for protocol therapy.\n\nExclusion Criteria:\n\n* Evidence of liver metastasis\n* Any bone involvement\n* Prior radiotherapy, cytotoxic or biologic systemic treatment\n* Any history of Asthma or COPD (chronic obstructive pulmonary disease) that needs systemic therapy with steroids for more than 2 weeks during the last 2 years.\n* Treatment with systemic steroids for more then 1 month during the last year.\n* Active smokers that are unable to quite smoking\n* Any treatment with investigational agent within 30 days prior to registration for protocol therapy.\n* Cerebrovascular accident, transient ischemic attack or myocardial infarction within 6 months prior to registration for protocol therapy.\n* Evidence of pulmonary embolism within 6 months prior to registration for protocol therapy.\n* Any history of solid or hematologic malignancies.\n* Patient with positive HIV serology at screening.\n* Female patient who are breastfeeding or have a positive pregnancy test at screening or at any time during the study.\n* Uncontrolled hypertension (\\> 150/100 mm Hg despite optimal medical therapy).\n* Evidence of ongoing cardiac dysrhythmias of NCI CTCAE (Common Toxicity Criteria for Adverse Effects) Version 3.0 grade 2.\n* Patients in whom radiation or surgery is indicated\n* Significant swallowing disorders.\n* Small bowel surgery.\n* Suspicion of absorption disruption as a result of abdominal radiation\n* Pre-existing malabsorption syndrome, irritable bowel syndrome or other clinical situation which could affect oral absorption.\n* Evidence of concurrent (\\< 5 years) second malignancy\n* Mental disorders.\n* Inability to give written informed consent.'}, 'identificationModule': {'nctId': 'NCT01627795', 'briefTitle': 'Safety and Efficacy of Oshadi D and Oshadi R for Malignant Mesothelioma Treatment', 'organization': {'class': 'INDUSTRY', 'fullName': 'Oshadi Drug Administration'}, 'officialTitle': 'A Single-center, Open Label Study for Evaluation of the Safety and Efficacy of Oshadi D and Oshadi R for Malignant Mesothelioma Treatment - A Phase IIa Study', 'orgStudyIdInfo': {'id': 'OS-MES-P2-01'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Oshadi D and Oshadi R', 'description': 'anti cancer agents', 'interventionNames': ['Drug: Oshadi D and Oshadi R']}], 'interventions': [{'name': 'Oshadi D and Oshadi R', 'type': 'DRUG', 'description': 'anti cancer agents', 'armGroupLabels': ['Oshadi D and Oshadi R']}]}, 'contactsLocationsModule': {'locations': [{'zip': '91240', 'city': 'Jerusalem', 'country': 'Israel', 'facility': 'Hadassah Medical Center', 'geoPoint': {'lat': 31.76904, 'lon': 35.21633}}], 'overallOfficials': [{'name': 'Hovav Nehushtan, Prof.', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Hadassah Medical Organization'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Oshadi Drug Administration', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}